BIOL - Biolase Inc Stock Price, Fair Value and News

0.17USD0.00 (0.00%)Delayed as of 08 May 2024, 12:02 pm ET

Market Summary

USD0.170.00

Delayedas of 08 May 2024, 12:02 pm

0.00%

BIOL Stock Price

View Fullscreen

BIOL RSI Chart

BIOL Valuation

Market Cap

5.5M

Price/Earnings (Trailing)

-0.27

Price/Sales (Trailing)

0.11

EV/EBITDA

-0.67

Price/Free Cashflow

-0.36

BIOL Price/Sales (Trailing)

BIOL Profitability

Operating Margin

34.02%

EBT Margin

-41.90%

Return on Equity

8.4K%

Return on Assets

-58.78%

Free Cashflow Yield

-278.58%

BIOL Fundamentals

BIOL Revenue

Revenue (TTM)

49.2M

Rev. Growth (Yr)

-3.99%

Rev. Growth (Qtr)

23.52%

BIOL Earnings

Earnings (TTM)

-20.6M

Earnings Growth (Yr)

45.99%

Earnings Growth (Qtr)

-16.06%

Breaking Down BIOL Revenue

52 Week Range

0.18

(Low)(High)

Last 7 days

13.3%

Last 90 days

-54.0%

Trailing 12 Months

-99.2%

How does BIOL drawdown profile look like?

BIOL Financial Health

Current Ratio

1.26

Debt/Equity

-47.7

Debt/Cashflow

-1.2

BIOL Investor Care

Shares Dilution (1Y)

3114.29%

Diluted EPS (TTM)

-33.71

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	48.8M	50.8M	49.7M	49.2M
2022	41.2M	44.3M	46.8M	48.5M
2021	26.1M	32.3M	35.3M	39.2M
2020	32.3M	26.5M	24.4M	22.8M
2019	46.5M	43.0M	40.7M	37.8M
2018	46.1M	45.6M	45.7M	46.2M
2017	51.7M	50.5M	48.1M	46.9M
2016	48.6M	50.6M	52.6M	51.8M
2015	47.0M	48.7M	47.2M	48.5M
2014	53.4M	49.3M	49.7M	47.7M
2013	59.6M	61.7M	60.3M	56.4M
2012	50.6M	51.1M	51.8M	57.4M
2011	30.7M	36.5M	43.4M	48.9M
2010	0	37.1M	30.8M	24.6M
2009	0	0	0	43.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Biolase Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 07, 2022	lord jonathan t md	sold	-2,652	0.75	-3,537	-
Apr 28, 2022	roper jess	back to issuer	-	-	-345	-
Apr 28, 2022	beaver john r	back to issuer	-	-	-554	president & ceo
Apr 28, 2022	lord jonathan t md	back to issuer	-	-	-1,395	-
Dec 15, 2021	lord jonathan t md	sold	-4,194	0.38	-11,038	-
Nov 30, 2021	beaver john r	bought	31,500	0.45	70,000	president & ceo
Aug 20, 2021	beaver john r	bought	21,350	0.61	35,000	president & ceo
May 19, 2021	beaver john r	bought	30,000	0.75	40,000	president & ceo
Dec 18, 2020	schuler education foundation	sold	-52,576	0.28	-187,774	-
Dec 17, 2020	schuler education foundation	sold	-160,348	0.28	-572,671	-

Which funds bought or sold BIOL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 03, 2024	HUNTINGTON NATIONAL BANK	unchanged	-	-	1.00	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 26, 2024	Kellett Wealth Advisors, LLC	unchanged	-	-17,767	3,618	-%
Apr 24, 2024	Zhang Financial LLC	sold off	-100	-15,450	-	-%
Mar 11, 2024	VANGUARD GROUP INC	new	-	12,242	12,242	-%
Feb 26, 2024	Virtu Financial LLC	new	-	14,000	14,000	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	15,476	15,476	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-43.9	-50.00	26.00	-%
Feb 14, 2024	Walleye Capital LLC	sold off	-100	-31,497	-	-%
Feb 14, 2024	Anson Funds Management LP	added	261	112,329	207,712	0.03%

Are Funds Buying or Selling BIOL?

Are funds buying BIOL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BIOL

No. of Funds

Unveiling Biolase Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 23, 2024	s.h.n. financial investments ltd.	9.9%	1,190,000	SC 13G
Feb 21, 2024	lind global fund ii lp	9.9%	1,190,000	SC 13G
Feb 14, 2024	anson funds management lp	8.1%	185,127	SC 13G
Feb 14, 2024	lytton laurence w	0.6%	26,824	SC 13G/A
Feb 13, 2024	lind global fund ii lp	0.4%	9,210	SC 13G/A
Oct 10, 2023	krefta edson roberto	10%	107,225	SC 13G/A
Sep 12, 2023	krefta edson roberto	6.8%	71,000	SC 13G
May 15, 2023	perkins capital management inc	2.1%	689,196	SC 13G/A
Feb 09, 2023	perkins capital management inc	11.9%	3,288,581	SC 13G
Jan 20, 2023	lytton laurence w	9.99%	2,461,094	SC 13G

Recent SEC filings of Biolase Inc

View All Filings

Date Filed	Form Type	Document
May 06, 2024	8-K	Current Report
Apr 23, 2024	424B4	Prospectus Filed
Apr 22, 2024	EFFECT	EFFECT
Apr 19, 2024	8-K	Current Report
Apr 19, 2024	POS AM	POS AM
Apr 11, 2024	POS AM	POS AM
Apr 04, 2024	424B3	Prospectus Filed
Apr 02, 2024	EFFECT	EFFECT
Mar 28, 2024	CORRESP	CORRESP
Mar 27, 2024	S-1/A	Initial Public Offering

Peers (Alternatives to Biolase Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	184.5B	40.3B	-4.60%	-4.35%	32.81	4.58	-2.84%	-3.08%
BDX	68.5B	19.7B	-3.65%	-5.69%	51.42	3.48	4.82%	-17.56%
ALGN	21.6B	3.9B	-9.77%	-6.38%	46.66	5.51	5.72%	46.72%
BAX	18.4B	14.9B	-15.25%	-20.81%	6.95	1.24	2.98%	207.68%
MID-CAP
ATR	9.9B	3.5B	5.58%	23.16%	31.71	2.8	6.16%	35.06%
HSIC	9.1B	12.5B	-1.81%	-10.76%	23.5	0.73	-0.61%	-18.83%
BIO	8.2B	2.7B	-13.87%	-26.12%	-12.81	3.06	-4.68%	82.43%
XRAY	5.9B	3.9B	-12.53%	-31.61%	-62.76	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	-0.62%	22.51%	-215.76	8.88	30.82%	65.57%
PDCO	2.3B	6.6B	-0.84%	-0.80%	12.05	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.97%	-19.30%	-1.87	0.4	7.94%	-1661.78%
ANIK	420.5M	166.7M	10.85%	9.31%	-5.09	2.52	6.67%	-456.34%
ANGO	245.9M	324.0M	-12.80%	-31.58%	-1.28	0.76	-3.19%	-337.41%
APYX	48.8M	52.3M	-6.00%	-59.48%	-2.61	0.93	17.61%	19.28%
AEMD	3.4M	3.7M	-25.71%	271.43%	-0.27	0.89	5.77%	8.23%

Biolase Inc News

Latest updates

Biolase Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	23.5%	13,490,000	10,921,000	14,286,000	10,467,000	14,051,000	12,010,000	12,235,000	10,166,000	12,407,500	9,531,000	9,134,000	8,116,000	8,520,000	6,539,000	2,938,000	4,783,000	10,182,000	8,646,000	8,645,000	10,326,000	13,045,000
Cost Of Revenue	38.9%	9,966,500	7,175,000	8,168,000	7,130,000	10,455,000	9,565,000	7,094,000	5,437,000	7,502,000	4,689,000	5,093,000	5,375,000	6,915,000	4,265,000	1,997,000	3,430,000	5,765,000	5,677,000	5,265,000	6,804,000	7,432,000
Gross Profit	-5.9%	3,523,500	3,746,000	6,118,000	3,337,000	3,596,000	2,445,000	5,141,000	4,729,000	4,905,500	4,842,000	4,041,000	2,741,000	1,605,000	2,274,000	941,000	1,353,000	4,417,000	2,969,000	3,380,000	3,522,000	5,613,000
Operating Expenses	15.5%	8,600,000	7,443,000	9,990,000	8,628,000	12,022,500	10,096,000	10,196,000	8,935,000	9,335,000	7,499,000	7,324,000	8,803,000	7,143,500	5,941,000	4,920,000	6,705,000	7,460,000	7,851,000	6,717,000	7,886,000	12,125,000
S&GA Expenses	24.3%	4,227,500	3,402,000	6,189,000	4,622,000	6,451,000	5,008,000	5,402,000	4,814,000	5,024,000	3,451,000	3,311,000	3,553,000	3,767,000	2,678,000	2,093,000	2,704,000	3,730,500	3,515,000	3,272,000	3,879,000	5,084,000
R&D Expenses	21.3%	1,651,500	1,362,000	1,444,000	1,547,000	2,088,500	1,979,000	1,653,000	1,544,000	1,542,500	1,540,000	1,162,000	1,803,000	1,051,000	963,000	690,000	991,000	1,095,500	1,126,000	1,124,000	1,424,000	1,276,000
EBITDA Margin	23.3%	-0.32	-0.42	-0.50	-0.56	-0.55	-0.47	-0.38	-0.29	-0.36	-0.42	-0.35	-0.58	-0.63	-	-	-	-	-	-	-	-
Interest Expenses	2.0%	499,000	489,000	460,000	470,000	409,000	367,000	366,000	377,000	443,000	442,000	438,000	448,000	443,000	972,000	-19,000	485,000	469,000	484,000	401,000	430,000	-
Income Taxes	-203.3%	-15,500	15,000	31,000	1,000	86,000	-17,000	23,000	17,000	71,500	14,000	-80,000	60,000	143,000	-15,000	53,000	-19,000	-112,500	26,000	28,000	15,000	-28,000
Earnings Before Taxes	-16.8%	-5,341,500	-4,574,000	-4,837,000	-5,848,000	-9,774,500	-8,404,000	-5,588,000	-4,759,000	-5,207,500	-3,262,000	-782,000	-6,841,000	-6,061,000	27,000	-4,644,000	-6,025,000	-3,695,000	-5,452,000	-3,871,000	-4,885,000	-6,947,000
EBT Margin	16.8%	-0.42	-0.50	-0.57	-0.61	-0.59	-0.51	-0.42	-0.34	-0.41	-0.48	-0.42	-0.67	-0.73	-	-	-	-	-	-	-	-
Net Income	-16.1%	-5,326,000	-4,589,000	-4,868,000	-5,849,000	-9,860,500	-8,387,000	-5,611,000	-4,776,000	-5,279,000	-3,276,000	-702,000	-6,901,000	-6,140,000	12,000	-4,697,000	-6,006,000	-3,582,500	-5,478,000	-3,899,000	-4,900,000	-6,919,000
Net Income Margin	17.1%	-0.42	-0.51	-0.57	-0.61	-0.59	-0.51	-0.43	-0.34	-0.41	-0.48	-0.42	-0.68	-0.74	-	-	-	-	-	-	-	-
Free Cashflow	10.9%	-2,468,000	-2,770,000	-3,919,000	-6,245,000	-6,092,000	-9,224,000	-6,886,000	-8,325,000	-3,415,000	-3,683,000	-3,812,000	-6,507,000	-1,366,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-9.4%	35.00	39.00	40.00	42.00	38.00	43.00	51.00	50.00	55.00	59.00	61.00	63.00	41.00	42.00	28.00	25.00	32.00	28.00	32.00	34.00	39.00
Current Assets	-10.5%	25.00	28.00	28.00	32.00	29.00	34.00	44.00	44.00	49.00	53.00	55.00	58.00	35.00	36.00	23.00	20.00	27.00	23.00	27.00	29.00	33.00
Cash Equivalents	-15.4%	7.00	8.00	7.00	7.00	4.00	10.00	20.00	22.00	30.00	34.00	37.00	41.00	18.00	19.00	6.00	2.00	6.00	2.00	4.00	3.00	8.00
Inventory	-17.3%	11.00	14.00	13.00	18.00	16.00	16.00	17.00	15.00	13.00	14.00	13.00	12.00	11.00	13.00	12.00	12.00	11.00	12.00	12.00	12.00	12.00
Net PPE	-8.7%	6.00	6.00	6.00	5.00	4.00	4.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00
Goodwill	0.9%	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Liabilities	0.9%	33.00	33.00	32.00	34.00	33.00	29.00	29.00	30.00	30.00	28.00	28.00	30.00	31.00	28.00	26.00	25.00	28.00	29.00	29.00	27.00	27.00
Current Liabilities	-0.6%	20.00	20.00	18.00	19.00	18.00	14.00	14.00	13.00	14.00	13.00	13.00	11.00	11.00	21.00	21.00	24.00	26.00	14.00	13.00	15.00	16.00
Long Term Debt	-	12.00	-	-	-	13.00	-	-	-	-	-	-	-	16.00	-	-	-	-	13.00	13.00	11.00	11.00
LT Debt, Current	-	2.00	-	-	-	1.00	-	-	-	-	-	-	-	-	13.00	14.00	14.00	13.00	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	16.00	-	-	-	-	13.00	13.00	11.00	11.00
Shareholder's Equity	-174.4%	-0.25	0.00	7.00	8.00	5.00	14.00	22.00	21.00	25.00	30.00	33.00	34.00	10.00	14.00	1.00	0.00	0.00	-	4.00	7.00	11.00
Retained Earnings	-1.7%	-316	-311	-306	-302	-296	-286	-277	-272	-267	-262	-258	-258	-251	-245	-245	-240	-234	-230	-225	-221	-216
Additional Paid-In Capital	1.5%	317	313	314	311	302	0.00	0.00	0.00	293	293	293	292	262	259	247	236	236	231	230	229	228
Shares Outstanding	50.8%	3.00	2.00	1.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-
Float	-	-	-	7.00	-	-	-	-	-	-	-	104	-	-	-	104	-	-	-	12.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	11.8%	-2,283	-2,588	-3,562	-5,658	-5,582	-6,546	-6,612	-8,021	-3,104	-3,598	-3,509	-6,499	-1,348	-2,108	-5,205	-4,134	-4,672	-1,447	-1,593	-5,034	-3,557
Share Based Compensation	-33.8%	182	275	84.00	691	612	591	891	209	174	191	369	928	1,003	848	800	719	768	770	447	757	906
Cashflow From Investing	98.4%	-3.00	-182	-357	-587	-471	-2,678	-274	-304	-311	-85.00	-303	-8.00	-18.00	3.00	-72.00	-9.00	-69.00	-13.00	-117	-8.00	-448
Cashflow From Financing	-76.4%	885	3,756	4,276	8,517	-32.00	-214	4,849	-	68.00	75.00	-14.00	29,825	-53.00	15,391	9,128	-117	8,305	-50.00	2,463	3.00	10,004

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BIOL Income Statement

2023-12-31

Consolidated Statements Of Operations And Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net revenue	$ 49,164	$ 48,462	$ 39,188
Cost of revenue	32,440	32,551	22,659
Gross profit	16,724	15,911	16,529
Operating expenses:
Sales and marketing	18,441	21,675	15,339
General and administrative	10,216	12,309	11,258
Engineering and development	6,004	7,265	6,048
Patent litigation mark-to-market	0	0	315
Total operating expenses	34,661	41,249	32,960
Loss from operations	(17,937)	(25,338)	(16,431)
Loss on foreign currency transactions	(351)	(438)	(452)
Interest expense, net	(2,361)	(2,749)	(2,224)
Gain on debt forgiveness	0	0	3,014
Other income, net	48	0	0
Non-operating (loss) gain, net	(2,664)	(3,187)	338
Loss before income tax provision	(20,601)	(28,525)	(16,093)
Income tax provision	(31)	(109)	(65)
Net loss	(20,632)	(28,634)	(16,158)
Other comprehensive loss items:
Foreign currency translation adjustments	180	(110)	(238)
Comprehensive loss	(20,452)	(28,744)	(16,396)
Net Income (Loss)	(20,632)	(28,634)	(16,158)
Deemed dividend on convertible preferred stock	(16,987)	(217)	(546)
Net loss attributable to common stockholders	$ (37,619)	$ (28,851)	$ (16,704)
Net loss per share attributable to common stockholders:
Basic	$ (29.44)	$ (418.13)	$ (283.12)
Diluted	$ (29.44)	$ (418.13)	$ (283.12)
Shares used in the calculation of net loss per share:
Basic	1,278	69	59
Diluted	1,278	69	59

BIOL Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,566	$ 4,181
Accounts receivable, less allowance of $244 and $2,164 as of December 31, 2023 and 2022, respectively	5,483	5,841
Inventory	11,433	15,884
Prepaid expenses and other current assets	1,381	3,053
Total current assets	24,863	28,959
Property, plant, and equipment, net	5,525	4,278
Goodwill	2,926	2,926
Right-of-use assets, leases	1,519	1,768
Other assets	268	255
Total assets	35,101	38,186
Current liabilities:
Accounts payable	6,065	5,786
Accrued liabilities	8,881	9,210
Deferred revenue, current portion	2,452	2,111
Current portion of term loans, net of discount	2,265	700
Total current liabilities	19,663	17,807
Deferred revenue	256	418
Warranty accrual	593	360
Non-current term loans, net of discount	11,782	13,091
Non-current operating lease liability	772	1,259
Other liabilities	79	362
Total liabilities	33,145	33,297
Mezzanine Equity
Total mezzanine equity	2,203	0
Commitments and contingencies —Note 7
Stockholders' equity:
Common stock, par value $0.001 per share; 180,000 shares authorized, 3,416 and 77 shares issued and outstanding as of December 31, 2023 and 2022, respectively	3	0
Additional paid-in capital, common stock	317,103	301,790
Accumulated other comprehensive loss	(553)	(733)
Accumulated deficit	(316,800)	(296,168)
Total stockholders' equity	(247)	4,889
Total liabilities, convertible redeemable preferred stock and stockholders' equity (deficit)	35,101	38,186
Series H Convertible Redeemable Preferred Stock
Mezzanine Equity
Preferred stock Value	346	0
Series J Convertible Redeemable Preferred Stock
Mezzanine Equity
Preferred stock Value	$ 1,857	$ 0

About Biolase Inc

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, therapy pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

CEO	Mr. John R. Beaver
WEBSITE	biolase.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	188

Biolase Inc Frequently Asked Questions

What is the ticker symbol for Biolase Inc? What does BIOL stand for in stocks?

BIOL is the stock ticker symbol of Biolase Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biolase Inc (BIOL)?

As of Tue May 07 2024, market cap of Biolase Inc is 5.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIOL stock?

You can check BIOL's fair value in chart for subscribers.

What is the fair value of BIOL stock?

You can check BIOL's fair value in chart for subscribers. The fair value of Biolase Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biolase Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIOL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biolase Inc a good stock to buy?

The fair value guage provides a quick view whether BIOL is over valued or under valued. Whether Biolase Inc is cheap or expensive depends on the assumptions which impact Biolase Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIOL.

What is Biolase Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, BIOL's PE ratio (Price to Earnings) is -0.27 and Price to Sales (PS) ratio is 0.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIOL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Biolase Inc's stock?

In the past 10 years, Biolase Inc has provided -0.695 (multiply by 100 for percentage) rate of return.